Dr Samantha Jaglowski talks to ecancer at the ASCO 2012 Annual Meeting, Chicago, about the early phase ibrutinib trial.

Ibrutinib, an irreversible inhibitor of the Bruton’s tyrosine kinase, treats chronic lymphocytic leukaemia by blocking the activation of B cells, ultimately leading to apoptosis.

Patients were treated in both a refractory and frontline setting with ibrutinib used as a single agent and in combination with ofatumumab. Early results showed response in all patients.